China Pharma Holdings (CPHI) Debt to Equity (2016 - 2025)
Historic Debt to Equity for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to $0.24.
- China Pharma Holdings' Debt to Equity fell 3779.29% to $0.24 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.24, marking a year-over-year decrease of 3779.29%. This contributed to the annual value of $0.33 for FY2024, which is 414.76% down from last year.
- According to the latest figures from Q3 2025, China Pharma Holdings' Debt to Equity is $0.24, which was down 3779.29% from $0.42 recorded in Q2 2025.
- Over the past 5 years, China Pharma Holdings' Debt to Equity peaked at $1.08 during Q3 2022, and registered a low of $0.24 during Q3 2025.
- Moreover, its 5-year median value for Debt to Equity was $0.42 (2025), whereas its average is $0.52.
- Per our database at Business Quant, China Pharma Holdings' Debt to Equity soared by 10064.41% in 2022 and then plummeted by 6342.72% in 2023.
- Quarter analysis of 5 years shows China Pharma Holdings' Debt to Equity stood at $0.72 in 2021, then decreased by 20.9% to $0.57 in 2022, then plummeted by 39.98% to $0.34 in 2023, then fell by 4.15% to $0.33 in 2024, then fell by 28.13% to $0.24 in 2025.
- Its last three reported values are $0.24 in Q3 2025, $0.42 for Q2 2025, and $0.37 during Q1 2025.